RenovoRx cites peer-reviewed case series on TAMP gemcitabine delivery in locally advanced pancreatic cancer
RNXT•RenovoRx cited a peer-reviewed case series in which two heavily pretreated patients with locally advanced pancreatic cancer showed evidence of tumor response, with improved disease markers and supportive imaging changes; no major procedure-related complications were reported.
1. Case series results
The peer-reviewed publication described use of RenovoRx’s TAMP platform and RenovoCath device to deliver gemcitabine in locally advanced pancreatic cancer. Two heavily pretreated patients showed evidence of tumor response, including improved disease markers and supportive imaging changes, and no major procedure-related complications were reported.
